Cargando…
Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
AIM: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). METHODS: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy...
Autores principales: | Carneiro Neto, Jose Abraão, Santos, Silvane Braga, Orge, Gloria Orge, Tanajura, Davi, Passos, Lucia, Oliveira, Cassius José, Andrade, Rosana, Melo, Cláudio Galeno de, Barroso, Ubirajara, Carvalho, Edgar M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428232/ https://www.ncbi.nlm.nih.gov/pubmed/29462596 http://dx.doi.org/10.1016/j.bjid.2017.10.009 |
Ejemplares similares
-
Clinical manifestations in HTLV-1 infected individuals without HAM/TSP: Results of an 8 years cohort
por: Tanajura, Davi, et al.
Publicado: (2014) -
Immunological and viral features in patients with overactive bladder indicate an early stage of myelopathy
por: Santos, Silvane B, et al.
Publicado: (2011) -
Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study
por: Carneiro Neto, José Abraão, et al.
Publicado: (2022) -
The clinical spectrum of HTLV-1 infection
por: Tanajura, Davi, et al.
Publicado: (2015) -
OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)